Table 1 Association Between Clinicopathologic Features and H.Pylori Status

Gender

0.287

Male

59(72.0)

48(64.0)

Female

23(38.0)

27(36.0)

Age

0.128

   <57.2 years

45(54.9)

32(42.7)

   ≥57.2 years

37(45.1)

43(57.8)

Tumor site

0.040

   Upper

31(37.8)

18(24.0)

   Middle or Lower

51(62.2)

57(76.0)

Tumor size (Mean ± SD)

5.64 ± 2.82

5.84 ± 2.99

0.671

Gross type

0.816

   Early GC I

1(1.2)

1(1.3)

   Early GC III

10(12.2)

7(9.3)

   Borrmann I

15(18.3)

12(16.0)

   Borrmann II

37(45.1)

32(42.7)

   Borrmann III

11(13.4)

15(20.0)

   Borrmann IV

8(9.8)

8(10.7)

Histological Differentiate

0.236

   Well

36(43.9)

28(37.3)

   Poorly

35(42.7)

31(41.3)

   Mucous/Signet-ring cell

11(13.4)

16(21.3)

Depth of tumor invasion

0.749

   T1

4(4.9)

2(2.7)

   T2

9(11.0)

9(12.0)

   T3

58(70.7)

54(72.0)

   T4

11(13.4)

10(13.3)

Lymph-node metastasis

0.039

   N0

30(36.6)

16(21.3)

   N1

29(35.4)

29(38.7)

   N2

14(17.1)

19(25.3)

   N3

9(11.0)

11(14.7)

Distant metastases

0.822

   M0

71(86.6)

64(84.0)

   M1

11(13.4)

11(16.0)

UICC stage

0.124

   I

10(12.2)

6(8.0)

   II

20(24.4)

13(17.3)

   III

32(39.0)

32(42.7)

   IV

20(24.4)

24(32.0)

surgery

0.943

   Curative

65(79.8)

62(85.3)

   palliative

17(20.7)

11(14.7)

Tumor marker

   CEA

0.026

<5 μg/L

64(11.0)

51(68.0)

≥5 μg/L

9 (78.0)

19(25.3)

   CA199

0.346

<30 μg/L

44(53.7)

44(58.7)

≥30 μg/L

12(14.6)

18(24.0)

   P53

0.827

positive

9(11.0)

8(10.7)

negative

40(48.8)

40(53.3)